Well Newborn
COVID-19
Breastfeeding/Human Milk
Scholarly Sessions
Public Health
Neonatology
Infectious Diseases
Epidemiology & Health Services Pathway
Community Pediatrics
Children with Chronic Conditions
Basic Science Pathway
Neurology
Immunizations/Delivery
General Pediatrics
Clinical Research Pathway
Allergy, Immunology and Rheumatology
Adolescent Medicine
Mark Schleiss, MD
Professor and American Legion and Auxiliary Heart Research Foundation Chair
Division of Pediatric Infectious Diseases and Immunology
University of Minnesota Medical School
University of Minnesota Medical School
St Paul, Minnesota, United States
Sallie Permar, MD, PhD
Professor and Chair, Department of Pediatrics
Pediatrics
Weill Cornell Medicine
New York City, New York, United States
The most important congenital viral infection in the developed world, and probably globally, is congenital cytomegalovirus (CMV). Congenital CMV is the most common infectious disease responsible for neurocognitive deficits in children, and is the leading infectious cause of sensorineural hearing loss. Although development of a vaccine has been a major public health goal for decades, development of a vaccine has been limited by emerging knowledge about the potential for re-infection of immune women during pregnancy with resultant transmission of new strains of viral to the fetus, leading to injury and long-term disability. Thus, there are unresolved questions about the protective role of pre-existing maternal immunity and the viral and host correlates of such immunity. Indeed, some experts suggest that the bulk of disability caused by congenital CMV occurs in the context of infections that occur in the face of preconception immunity. If natural immunity does not protect, then how can a vaccine - which would need to induce immune responses superior to "natural immunity" - succeed?
To address these controversies, advances in molecular virology and viral immunology research that explore these topics will be presented at this symposium, along with a summary of the CMV vaccines that are currently in clinical trials. A major emphasis will be placed on how this new knowledge is likely to have an impact on the health of children, particularly with respect to long-term disabilities, but other topics, including health policy issues (CMV as a disease of health disparities) and adolescent vaccination questions (how to incorporate another vaccine into the routine schedule) will be reviewed. Policy issues and translational approaches in clinical trials will be integrated with basic science data (the virology and molecular immunology of CMV) to ensure an eclectic, but accessible and informative, program. This state-of-the-art plenary will be of broad appeal to a large number of academic pediatricians. The session will consist of invited lectures from internationally recognized, NIH-funded leaders engaged in study of this topic.
Presenter: Mark R. Schleiss, MD – University of Minnesota Medical School
Presenter: Mark R. Schleiss, MD – University of Minnesota Medical School
Presenter: William Britt, MD – Univ of Alabama School of Medicine
Presenter: Sallie Permar, MD, PhD – Weill Cornell Medicine
Presenter: Stanley Plotkin, MD – University of Pennsylvania
Presenter: -- --
Presenter: -- --